Featured Article

Why Quantifying the Financial Value of RBQM Has Been So Hard- and What This Study Did Differently

In this video interview, Sylviane de Viron of CluePoints and Abigail Dirks of Tufts CSDD explain how combining real-world deployment data with eNPV modeling finally made it possible to put a number on the financial value of RBQM—and why oncology was chosen as a conservative starting point.

Guide

NEW: The Ultimate Guide to Modern, Regulatory-Grade RBQM

Press Release
CluePoints Shortlisted for 2026 Scrip Awards Following 2023 and 2025 Wins
Press Release
CluePoints Launches Three AI-Led Clinical Data Review Capabilities, Co-Innovated with a Top 10 Pharmaceutical Company
Press Release
CluePoints Appoints Martin Magazzolo as Chief Commercial Officer